SUMMARY Herpes genitalis is an infection associated with considerable morbidity. Acyclovir, though effective, must be taken daily to prevent recurrences. The effects of interferon on this infection were therefore investigated. In a randomised double blind study, 31 patients with first episodes of genital herpes infection were studied to assess the effect of interferon on the presenting episode and on recurrences. Interferon (5 X 106 IU) was administered once daily subcutaneously during a five day "treatment" period followed by a three month "maintenance" period (1 x 106 IU three times weekly). Interferon had no effect on first episode herpetic attacks. During interferon administration women showed a trend towards reduced healing time and viral shedding in recurrences, but the differences were not significant and no effect was noted in women after administration of interferon. Interferon reduced assessed healing time and viral shedding in recurrences, however, in men (p=OO5) during interferon administration, and this continued as a trend after treatment.
Introduction
Until recently, no effective treatment was available for genital herpes simplex virus (HSV) infections. Acyclovir (acycloguanosine) ointment has been effective in first episodes of herpes, particularly in women,' 2 and has accelerated healing in men with recurrent herpes,3 and acyclovir tablets have been effective in treating first episode genital herpes4 and recurrent herpes,56 and supressing recurrent disease successfully if taken daily.7 8 The drug is not curative, and the high cost of treatment as well as the unknown toxicity of long term administration9 make it a less than satisfactory solution to the problem.
Recombinant interferon a 2 can be produced in virtually limitless quantities, and at "low" doses it has minimal side effects such as fever, chills, and muscle aches, which occur in most patients for one to three days of the treatment period. This study was therefore undertaken to assess the effect of parenterally administered interferon a 2 on the clinical course of first episodes of genital herpes infection, and on recurrences occurring in the same patients. Patients Virolo,gical and serological methods Lesions were cultured by rolling a rayon swab over the bases of two lesions, and the swabs were vigorously agitated in 1 ml Hank's balanced salt solution viral transport medium. The supernatant was transferred into two tubes of W 138 cell cultures containing medium 199 with 2% fetal bovine serum and penicillin 100 M/ml, streptomycin lOOp g/ml, and amphotericin 1 ts g/ml. The two inoculated tubes were observed for cytopathogenic effect on alternate days for 14 days. Jack Mendelson, BYA Clecner, and Sharon Eiley We identified and typed isolates as HSV-1 or HSV-2 by indirect immunofluorescence with monoclonal antibodies using the "Herpes ID Kit" (Armand Frappier Institute, Laval, Quebec, Canada). We tested serum complement fixation antibodies to HSV-1 and HSV-2 when patients entered the study.
Material for HSV cultures was taken from the endocervix of all women patients and from the urethra of all men. Any extragenital lesions were also cultured.
FOLLOW UP FOR RECURRENCES
We followed up all patients during the maintenance phase and at monthly intervals after the end of the maintenance phase for a period of six months. Immediately a recurrence occurred, we examined and followed up the patient.
STATISTICAL ANALYSIS
We analysed data by Wilcoxon's non-parametric rank sum test for two independent samples.
Results

STUDY POPULATION
Thirty one patients (13 men, 18 women) were enrolled in the study from June 1983 to January 1984. Two women were excluded during the maintenance phase of the study because of non-compliance. The remaining 29 patients completed their entire course of interferon treatment.
Differentiation between the side effects of the interferon and the symptoms of the disease was not possible while the study was blind, but the differences became evident when the code was broken. Most of the symptoms listed below lasted for one to three days and in a few patients ended after the first week. Of the 14 patients treated with interferon, 12 had fever, 10 headache, 11 chills, seven myalgia, five nausea, three vomiting, eight fatigue, eight anorexia, and one diarrhoea. All had neutropenia during the treatment On initial presentation herpetic lesions at sites other than the penis or vulva were noted in the urethras of three men, the rectums of two men, the cervices of nine women, and the oral labia of one woman. Table III shows that interferon had no effect on the Table III shows that, though there was a definite trend for duration of viral shedding and time to healing to be shorter during interferon administration in women, the differences were not significant. No effect was noted in women after administration of interferon was stopped.
EFFECTS OF INTERFERON ON FIRST EPISODE INFECTIONS
Discussion
The results of this study clearly show that interferon a2 had no effect on first episode genital herpes infections in either men or women. Though it did not affect the number of recurrences, it did have a significant effect on their nature in men during the administration of interferon. The time to healing and duration of viral shedding were up to six months shorter in men after administration of' the maintenance phase of interferon, though the reduction in duration of viral shedding was not significant. The number of patients was small, and further experiments are needed to confirm these results. There was a trend towards shortened viral shedding and healing times in women receiving interferon, but these results were not significant. No trend was noted in women after maintenance treatment with interferon was stopped. A sex difference in response to the treatment of genital hierpes has been noted previously, as decreased healing time was seen only in men receiving acyclovir ointment in recurrent infections. An experimental model of genital herpes infection in guinea pigs (Kern, unpublished observation) using human recombinant interferon a A (Roche) showed that, if the interferon was administered for seven davs beginning 24 hours after inoculation of the animais, the course of the initial episode was strikingly altered.
and there was a decrease in the number of recurrences after the interferon was discontinued. If interferon was not administered until 72 hours after viral inoculation. however, the effect on the initial episode was less pronounced, and there was no effect on recurrences after the seven days of interferon treatment. These data suggest that interferon may act more as an immunomodulator than as an antiviral agent in this animal model, and that the way in which the initial Jack Mendelson, BYA Clecner, and Sharon Eiley episode is treated with interferon can affect the subsequent course of the disease, namely the recurrences.
Interferon was well tolerated at the doses used, but was administered for a long time (five days ot treatment and three months of maintenance doses given three times weekly), which clearly is not a practical regimen. Furthermore, having to inject interferon makes it inconvenient to use for a long time. The dose and duration of interferon treatment were arbitrarily decided, however, and administration for a much shorter "treatment" time with occasional "booster" injections may be adequate. Additional trials with various dosage schedules are required to confirm this. Interestingly, other workers have shown that interferona 2 has no effect on recurrent herpetic infections.'" In that study, however, unlike the study published here, interferon was not given during the first episode of the infections. In the study reported here, interferon given during the first episode of infection possibly had an immunomodulating rather than antiviral action, which manifested itself by an effect on the recurrences. More needs to be learned about the biological activities of interferon before the above phenomenon can be understood.
The results of this study suggest a possible new approach to the treatment of genital herpes. In men there was a significant effect on recurrences during administration of interferon and a beneficial trend for six months after maintenance treatment. Recombinant interferona2 was used in this study but other interferons, such as 3 or-7, may possibly be more effective in managing genital herpes infections.
